Zach Reitano, CEO of RO, revealed soaring demand for the company's oral GLP-1 medication on Bloomberg's "The Close." He attributes the surge to the pill's approachability and affordability. The starting price has plummeted from around $1,300 eight months ago to just $149, making it a more accessible option for many patients.

This news arrives amid a frenzy surrounding GLP-1 drugs, initially developed for diabetes but now widely used for weight loss. Companies like Novo Nordisk and Eli Lilly have seen their market caps explode due to the popularity of injectable versions. RO's offering gives patients another option in the weight loss journey.

Reitano's comments signal a shift in the weight loss market. Oral medications could broaden access, potentially challenging the dominance of injectable drugs. The lower price point is a huge advantage. Investors should watch how this impacts RO's market share and the strategies of competitors in the coming months.